Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM9OZWQ)

Drug Name
Lovastatin Drug Info
Synonyms
lovastatin; 75330-75-5; mevinolin; Mevacor; Lovalip; Monacolin K; Lovalord; Mevinacor; Altoprev; Nergadan; Artein; Altocor; 6alpha-Methylcompactin; MK-803; Hipovastin; Lovastatine; Lovasterol; Paschol; Lipivas; Closterol; Teroltrat; Tecnolip; Rovacor; Cholestra; Rodatin; Lozutin; Lipofren; Lestatin; Hipolip; Colevix; Sivlor; Taucor; Lipdip; Belvas; Mevlor; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatinum; Lovastatina; Lovastin; MSD 803; MK 803; 6 alpha-Methylcompactin; UNII-9LHU78OQFD; Altocor; Liposcler; Mevinolin; Rextat; Sivlor;Taucor; Monakolin K; MK803; Advicor (TN); Altocor (TN); Altoprev (TN); L-154803; Lovastatin & Primycin; ML-530B; Mevacor (TN); Mevinolin from Aspergillus sp; Statosan (TN); Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6-Methylcompactin; Aspirin/lisinopril/ lovastatin fixed-dose combination
Therapeutic ClassAnticholesteremic Agents
Cross-matching ID
PubChem CID
53232
ChEBI ID
CHEMBL503
CAS Number
CAS 75330-75-5
TTD Drug ID
D06WTZ
VARIDT Drug ID
DR00410
INTEDE Drug ID
DR0986
ACDINA Drug ID
D00377

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.56 0.00e+0 19/20 (95%) MSMO1;DHCR24;SQLE;...
GnRH signaling pathway 1.89 1.64e-2 80/93 (86.02%) JUN;GNAS;ADCY1;...
Estrogen signaling pathway 1.86 1.83e-2 119/137 (86.86%) HSPA1A;HSPA8;JUN;...
Insulin secretion 1.84 1.92e-2 75/86 (87.21%) GNAS;ADCY1;PLCB3;...
Endocrine and other factor-regulated calcium reabsorpti... 1.82 2.19e-2 49/53 (92.45%) GNAS;PLCB3;PRKCB;...
Terpenoid backbone biosynthesis 1.79 2.37e-2 18/22 (81.82%) HMGCS1;IDI1;HMGCR;...
Aldosterone synthesis and secretion 1.79 2.04e-2 85/98 (86.73%) GNAS;ADCY1;PLCB3;...
Inositol phosphate metabolism 1.78 1.92e-2 66/73 (90.41%) PLCB3;INPPL1;PTEN;...
Salivary secretion 1.78 1.83e-2 76/93 (81.72%) GNAS;ADCY1;PLCB3;...
Gastric acid secretion 1.77 1.86e-2 63/76 (82.89%) GNAS;ADCY1;PLCB3;...
Phosphatidylinositol signaling system 1.77 1.79e-2 82/97 (84.54%) PLCB3;PRKCB;INPPL1;...
Thyroid hormone synthesis 1.75 2.19e-2 66/75 (88%) GNAS;ADCY1;PLCB3;...
MicroRNAs in cancer 1.73 2.78e-2 146/310 (47.1%) HMOX1;DDIT4;CDC25B;...
Parathyroid hormone synthesis, secretion and action 1.71 3.52e-2 98/106 (92.45%) JUND;RXRA;MAFB;...
Progesterone-mediated oocyte maturation 1.68 4.53e-2 75/100 (75%) CDC25B;PLK1;CCNB2;...
Gap junction 1.67 4.32e-2 72/88 (81.82%) GNAS;ADCY1;PLCB3;...
Oocyte meiosis 1.65 4.77e-2 90/129 (69.77%) CDC20;PLK1;CCNB2;...
Morphine addiction 1.62 4.86e-2 80/91 (87.91%) GABRE;GNAS;ADCY1;...
Type II diabetes mellitus 1.61 4.75e-2 42/46 (91.3%) PKM;IRS2;PIK3R3;...
Carbohydrate digestion and absorption 1.61 5.00e-2 37/47 (78.72%) PLCB3;PRKCB;ATP1A1;...
Taurine and hypotaurine metabolism -1.57 4.87e-2 8/11 (72.73%) CDO1;ADO;GAD1
Complement and coagulation cascades -1.58 4.83e-2 76/85 (89.41%) PLAU;MASP2;C8A;...
Systemic lupus erythematosus -1.60 4.01e-2 45/135 (33.33%) C8B;CD28;CD86;...
Coronavirus disease -1.61 3.85e-2 215/232 (92.67%) IKBKE;RPS5;CSF2;...
Arginine and proline metabolism -1.64 3.11e-2 39/50 (78%) CNDP2;ODC1;OAT;...
Kaposi sarcoma-associated herpesvirus infection -1.64 3.17e-2 172/193 (89.12%) CCR1;IKBKE;CSF2;...
Ribosome -1.67 2.45e-2 113/158 (71.52%) MRPL34;RSL24D1;MRPL2;...
Viral myocarditis -1.69 2.10e-2 53/60 (88.33%) LAMA1;CASP8;ABL2;...
Hepatitis C -1.71 1.62e-2 139/157 (88.54%) CFLAR;CASP3;OAS1;...
NOD-like receptor signaling pathway -1.71 1.70e-2 145/181 (80.11%) TRAF5;TNFAIP3;IFNAR2;...
RNA transport -1.72 1.80e-2 128/186 (68.82%) PRMT5;NMD3;NUP93;...
Epstein-Barr virus infection -1.72 1.80e-2 189/202 (93.56%) HES1;HLA-A;GADD45A;...
Type I diabetes mellitus -1.73 1.80e-2 38/43 (88.37%) CPE;CD28;CD86;...
Influenza A -1.74 1.68e-2 156/172 (90.7%) HLA-DRA;AKT3;TRIM25;...
NF-kappa B signaling pathway -1.75 1.67e-2 90/104 (86.54%) GADD45A;TRAF5;TNFAIP3;...
Allograft rejection -1.76 1.52e-2 32/38 (84.21%) CD28;CD86;HLA-A;...
Rheumatoid arthritis -1.81 1.05e-2 78/93 (83.87%) ITGB2;CD28;CXCL6;...
RIG-I-like receptor signaling pathway -1.83 8.18e-3 64/70 (91.43%) TRIM25;NFKBIA;ATG12;...
Graft-versus-host disease -1.85 7.20e-3 32/42 (76.19%) CD28;CD86;HLA-A;...
TNF signaling pathway -1.87 8.00e-3 103/112 (91.96%) CFLAR;CASP3;IL18R1;...
Cytosolic DNA-sensing pathway -1.92 2.25e-3 52/63 (82.54%) POLR3D;PYCARD;POLR2F;...
Autoimmune thyroid disease -1.93 2.57e-3 46/53 (86.79%) CD28;CD86;HLA-A;...
RNA polymerase -1.93 3.00e-3 23/31 (74.19%) POLR3D;POLR1B;POLR2F;...
Cytokine-cytokine receptor interaction -1.94 1.80e-3 246/295 (83.39%) IL27RA;CSF1;ACKR3;...
Herpes simplex virus 1 infection -1.97 2.25e-3 165/498 (33.13%) IFNGR2;IKBKE;HLA-A;...
Viral protein interaction with cytokine and cytokine re... -2.01 3.00e-3 84/100 (84%) CSF1;ACKR3;CSF1R;...
Ribosome biogenesis in eukaryotes -2.07 0.00e+0 52/108 (48.15%) FBL;POP5;NVL;...
Malaria -2.09 0.00e+0 44/50 (88%) TLR2;COMP;IL6;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 40uM 6H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Bone marrow
Normal (Stromal)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HS-27a CVCL_0313 Homo sapiens 1.11uM - 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM - 40uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 40uM 6H
HT-29 CVCL_0320 Homo sapiens 10uM - 40uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 40uM 6H
MDST8 CVCL_1400 Homo sapiens 40uM 6H
NCI-H508 CVCL_1561 Homo sapiens 40uM 6H
SNU-1040 CVCL_5001 Homo sapiens 40uM 6H
SNU-C4 CVCL_5008 Homo sapiens 40uM 6H
SNU-C5 CVCL_5009 Homo sapiens 40uM 6H
SW480 CVCL_0546 Homo sapiens 40uM 6H
SW620 CVCL_0547 Homo sapiens 40uM 6H
SW948 CVCL_0550 Homo sapiens 40uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 40uM 6H
HT115 CVCL_1294 Homo sapiens 40uM 6H
RKO CVCL_0504 Homo sapiens 40uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 40uM 6H
SNG-M CVCL_1707 Homo sapiens 40uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 40uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 1.11uM - 40uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM - 40uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM - 40uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 40uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 40uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 40uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 40uM 6H
T3M-10 CVCL_1729 Homo sapiens 40uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 40uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 40uM 6H
HCC515 CVCL_5134 Homo sapiens 10uM - 40uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 40uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 40uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 40uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 40uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 40uM 6H
OV7 CVCL_1623 Homo sapiens 40uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 40uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 40uM 6H
RMUG-S CVCL_1666 Homo sapiens 40uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 40uM 6H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 40uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 40uM 6H
PL-21 CVCL_2161 Homo sapiens 40uM 6H
SKM-1 CVCL_0010 Homo sapiens 1.11uM - 40uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 1.11uM - 40uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM - 40uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM - 40uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM - 40uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 40uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 40uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 40uM 6H